tiprankstipranks
Trending News
More News >
Delivra Health Brands Inc. (TSE:DHB)
:DHB
Advertisement

Delivra Health Brands (DHB) AI Stock Analysis

Compare
98 Followers

Top Page

TSE:DHB

Delivra Health Brands

(DHB)

Rating:56Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Delivra Health Brands is in a recovery phase with improving financial metrics and strategic corporate actions. However, the poor valuation due to negative earnings and lack of dividends weigh heavily on the score. The technical analysis suggests neutral market sentiment, and corporate events are positive, indicating potential for future growth.

Delivra Health Brands (DHB) vs. iShares MSCI Canada ETF (EWC)

Delivra Health Brands Business Overview & Revenue Model

Company DescriptionDelivra Health Brands (DHB) is a company operating in the health and wellness sector, specializing in the development and commercialization of topical delivery systems. The company's core products focus on providing innovative and effective solutions for pain relief, skin care, and personal well-being through advanced delivery technologies.
How the Company Makes MoneyDelivra Health Brands generates revenue primarily through the sale of its topical products, which are distributed across various retail and online channels. The company capitalizes on its proprietary delivery systems to offer differentiated products that appeal to consumers seeking effective health and wellness solutions. Additionally, DHB may engage in strategic partnerships or licensing agreements with other companies to expand its market reach and enhance its product offerings. These collaborations can contribute to revenue generation by enabling access to new markets and customer segments.

Delivra Health Brands Financial Statement Overview

Summary
Delivra Health Brands is showing positive revenue growth and improved gross profit margins, but struggles with negative EBIT margins and thin net profit margins. The balance sheet is stable with manageable debt levels, and cash flow improvements indicate better operational efficiency.
Income Statement
65
Positive
Delivra Health Brands has shown positive trends in revenue growth, with an increase from $9.79M in 2023 to $12.57M in TTM, resulting in a 28.4% growth rate. The gross profit margin has improved significantly to 47.2% in TTM, indicating better cost management. However, the company is struggling with negative EBIT margins and thin net profit margins, which could be a concern for long-term profitability.
Balance Sheet
60
Neutral
The balance sheet shows a relatively stable equity base with a debt-to-equity ratio of 0.50 in TTM, indicating modest leverage. The equity ratio stands at 50.9%, showing solid equity financing. However, the return on equity is minimal at 0.14%, reflecting the challenge in generating returns from equity capital.
Cash Flow
70
Positive
The cash flow statement highlights a positive trend in free cash flow, which increased from negative values to $407K in TTM. The operating cash flow to net income ratio is high, indicating strong cash generation relative to reported profits. The company needs to maintain this momentum to ensure liquidity and operational flexibility.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue12.38M9.79M8.14M7.96M7.78M
Gross Profit6.40M3.49M485.00K-297.00K-1.62M
EBITDA2.35M1.40M-4.25M-7.04M-55.40M
Net Income876.00K-184.00K-7.01M-28.54M-79.86M
Balance Sheet
Total Assets10.05M10.56M11.59M19.06M57.84M
Cash, Cash Equivalents and Short-Term Investments4.20M2.73M1.11M5.14M1.41M
Total Debt2.03M1.96M2.11M2.16M5.97M
Total Liabilities4.86M7.17M8.21M9.09M21.27M
Stockholders Equity5.19M3.39M3.37M9.98M33.52M
Cash Flow
Free Cash Flow756.00K-1.13M-4.46M-9.68M-24.67M
Operating Cash Flow756.00K-1.09M-4.44M-9.65M-18.36M
Investing Cash Flow11.00K2.91M1.35M12.27M-3.64M
Financing Cash Flow594.00K-255.00K-309.00K446.00K3.17M

Delivra Health Brands Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.21
Price Trends
50DMA
0.21
Negative
100DMA
0.20
Positive
200DMA
0.19
Positive
Market Momentum
MACD
<0.01
Positive
RSI
45.24
Neutral
STOCH
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.21, and above the 200-day MA of 0.19, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.24 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$8.67M-63.75%9.34%69.69%
56
Neutral
C$6.72M181.82-3.45%4.04%80.24%
56
Neutral
$6.23B21.98-28.61%4.90%10.73%-32.66%
48
Neutral
C$67.98M-971.43%571.23%64.25%
46
Neutral
C$7.43M-112.06%46.27%20.75%
43
Neutral
C$6.22M90.000.83%-8.84%-96.82%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:DHB
Delivra Health Brands
0.22
-0.03
-12.00%
TSE:BBM
Blueberries Medical
0.02
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.19
-0.29
-60.42%
IMCC
IM Cannabis Corp
2.81
0.35
14.23%
TSE:CANB
CanadaBis Capital
0.04
-0.02
-33.33%

Delivra Health Brands Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Delivra Health Expands U.S. Reach Through QVC Partnership
Positive
Jun 2, 2025

Delivra Health Brands has expanded its U.S. presence by partnering with QVC, a major televised and online shopping network. This collaboration will enhance the distribution and visibility of its Dream Water Snoozeberry Sleep Shots, potentially increasing brand loyalty and consumer engagement through QVC’s unique shopping experience.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Business Operations and Strategy
Delivra Health Brands Enhances Investor Relations with New Partnerships
Positive
May 22, 2025

Delivra Health Brands Inc. has engaged Global One Media and Bergskogar Limited for investor relations services to enhance its digital marketing and global business development efforts. These collaborations are expected to strengthen Delivra Health’s market presence and visibility, potentially impacting its operations and stakeholder interests positively.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Delivra Health Achieves Positive Q3 EBITDA Amid Strategic Marketing Push
Positive
May 21, 2025

Delivra Health Brands reported a positive adjusted EBITDA for the third quarter of fiscal 2025, driven by strong marketing momentum and growth in units sold. The company achieved a 3% year-over-year revenue increase and expanded its Dream Water product offerings in Canada, while also launching successful marketing campaigns for its LivRelief brand. Despite a reduction in gross profit margin due to higher costs, Delivra Health’s strategic investments in marketing and product innovation have laid a strong foundation for future growth.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Delivra Health Expands Dream Water® Brand with New Product Launch in Middle East
Positive
May 8, 2025

Delivra Health Brands Inc. is expanding its Dream Water® product line by launching 60-Count Sleep Gummies in the Middle Eastern markets through its Kuwait-based distributor. This strategic move is expected to enhance the brand’s presence and growth in new markets, leveraging the success of its sleep solutions in Canada and the U.S., and offering more choices to consumers in the region.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025